Showing results (801-810 of 2,510) with videos related to
Sort By:
Pageof 251
Journal of the International AIDS Society|November 14, 2014
Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 studyNiklaus Daniel Labhardt, Molisana Cheleboi, Olatunbosun Faturyiele, et al.Journal of the International AIDS Society|November 14, 2014
Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL studyPedro Cahn, Jaime Andrade Villanueva, Jose Arribas, et al.Journal of the International AIDS Society|November 14, 2014
The prevalence and predictive value of dipstick urine protein in HIV-positive persons in EuropeAmanda Mocroft, Lene Ryom, Giuseppe Lapadula, et al.Journal of the International AIDS Society|November 14, 2014
Investigating presentations and outcomes of a joint HIV-renal clinicJake Scott, Deborah WilliamsJournal of the International AIDS Society|November 14, 2014
Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143Juan Berenguer, Ferdinand Wit, Per O Jansson, et al.Journal of the International AIDS Society|November 14, 2014
Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in ItalyAndrea Antinori, Marco Borderi, Roberto Cauda, et al.Journal of the International AIDS Society|November 14, 2014
Sex differences in apolipoprotein A1 and nevirapine-induced toxicityAline Marinho, Clara Dias, Alexandra Antunes, et al.Journal of the International AIDS Society|November 14, 2014
Proton 1H- and Phosphorus 31P-MR spectroscopy (MRS) in asymptomatic HIV-positive patientsGundolf Schuettfort, Elke Hattingen, Ulrich Pilatus, et al.Journal of the International AIDS Society|November 14, 2014
Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapyIgnacio Pérez Valero, Alicia Gonzalez Baeza, Juan Antonio Hernandez-Tamames, et al.Journal of the International AIDS Society|November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?Andrew Hill, Saye Khoo, David Back, et al.Pageof 251